Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ

The incidence rates of cervical adenocarcinoma have been increasing over the last two decades, contrary to those of squamous cell carcinoma. This trend is particularly evident among females aged <40 years and has occurred despite extensive cytology-based screening programs. The aim of the present retrospective database study was to investigate adenocarcinoma in situ (AIS) with respect to previous cytological results, high-risk (HR) human papillomavirus (HPV) infections and histological results from AIS-adjacent squamous mucosa. Databases were used to identify 32 female patients with AIS treated for various conditions between 2009 and 2012 at the Department of Gynecology, Uppsala University Hospital (Uppsala, Sweden) and previous cytological, HPV and histological results. Of the individuals in the study, 64.3% had a previously recorded cytological result showing squamous cell abnormalities; five had glandular cell abnormalities (18%) and two had AIS (7.1%). Among the patients with available HPV results, 95% were HR-HPV-positive; HPV18/45 predominated (77%), followed by HPV16 (27%). The patients with multiple HPV infections were aged ≤32 years, while patients aged ≥38 years were only infected with HPV18/45. All but three patients had cervical intraepithelial neoplasia (CIN) in the AIS-adjacent squamous mucosa, 79% of which was CIN2 or worse. The present retrospective database study suggests that AIS is detected at screening mainly due to simultaneous squamous precursor lesions and that HPV18/45 infection is an increasing cofactor for AIS in older patients. HPV analyses of glandular precursor lesions aid in the identification of female individuals at risk of progression to invasive disease, and thus have a favorable effect on adenocarcinoma prevention, together with vaccination.

[1]  R. Richart Cervical intraepithelial neoplasia. , 1973, Pathology annual.

[2]  M. Henry,et al.  The uterine cervix , 2015 .

[3]  Katherine E Henson,et al.  Risk of Suicide After Cancer Diagnosis in England , 2018, JAMA psychiatry.

[4]  S. Kulasingam,et al.  Cervical cancer trends in the United States: a 35-year population-based analysis. , 2012, Journal of women's health.

[5]  K. Münger,et al.  A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer , 2012, Proceedings of the National Academy of Sciences.

[6]  U. Gyllensten,et al.  Primary high-risk HPV screening for cervical cancer in post-menopausal women. , 2012, Gynecologic oncology.

[7]  C. Trimble,et al.  New technologies for cervical cancer screening. , 2012, Best practice & research. Clinical obstetrics & gynaecology.

[8]  Mark Schiffman,et al.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. , 2011, The Lancet. Oncology.

[9]  J. Palmgren,et al.  Prospective study of human papillomavirus and risk of cervical adenocarcinoma , 2010, International journal of cancer.

[10]  U. Gyllensten,et al.  HPV test shows low sensitivity of Pap screen in older women. , 2010, The Lancet. Oncology.

[11]  K. Hellman,et al.  Invasive carcinoma of the uterine cervix associated with pregnancy , 2010, Cancer.

[12]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[13]  Ulf Gyllensten,et al.  Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[14]  E. Wilander,et al.  Self-sampling of the vaginal fluid at home combined with high-risk HPV testing , 2009, British Journal of Cancer.

[15]  S. Wacholder,et al.  Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study , 2009, BMJ : British Medical Journal.

[16]  U. Gyllensten,et al.  Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[17]  J. Cuzick,et al.  Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older , 2009, International journal of cancer.

[18]  Joakim Dillner,et al.  Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study , 2008, BMJ : British Medical Journal.

[19]  P. Sparén,et al.  Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. , 2008, Journal of the National Cancer Institute.

[20]  S. Wacholder,et al.  Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. , 2008, Journal of the National Cancer Institute.

[21]  Jose Jeronimo,et al.  Human papillomavirus and cervical cancer , 2007, The Lancet.

[22]  M. Plummer,et al.  A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. , 2007, The Journal of infectious diseases.

[23]  J. Green,et al.  Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: Collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies , 2007, International journal of cancer.

[24]  Xavier Castellsagué,et al.  Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. , 2006, Journal of the National Cancer Institute.

[25]  F. Bray,et al.  Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries , 2005, Cancer Epidemiology Biomarkers & Prevention.

[26]  H. Cubie,et al.  The role of human papillomavirus testing in cervical screening. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[27]  J. T. Cox,et al.  Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening , 2004, Obstetrics and gynecology.

[28]  U. Gyllensten,et al.  Real-Time PCR-Based System for Simultaneous Quantification of Human Papillomavirus Types Associated with High Risk of Cervical Cancer , 2003, Journal of Clinical Microbiology.

[29]  M. Plummer,et al.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.

[30]  M. Sherman,et al.  The 2001 Bethesda system: Terminology for reporting results of cervical cytology , 2002 .

[31]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[32]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[33]  D. Luesley,et al.  Adenocarcinoma in situ of the cervix-controversies in diagnosis and treatment. , 2001, Journal of lower genital tract disease.

[34]  D M Parkin,et al.  International trends in incidence of cervical cancer: II. Squamous‐cell carcinoma , 2000, International journal of cancer.

[35]  H. Adami,et al.  Trends in cancer of the cervix uteri in Sweden following cytological screening , 1999, British Journal of Cancer.

[36]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[37]  R. Ashfaq,et al.  ThinPrep Pap Test , 1999, Acta Cytologica.

[38]  H. Adami,et al.  International incidence rates of invasive cervical cancer after introduction of cytological screening , 1997, Cancer Causes & Control.

[39]  R. Marks,et al.  Squamous cell carcinoma , 1996, The Lancet.

[40]  R. Jaworski Endocervical glandular dysplasia, adenocarcinoma in situ, and early invasive (microinvasive) adenocarcinoma of the uterine cervix. , 1990, Seminars in diagnostic pathology.

[41]  L. Twiggs,et al.  Human Papillomavirus DNA in Glandular Dysplasia and Microglandular Hyperplasia: Presumed Precursors of Adenocarcinoma of the Uterine Cervix , 1989, Obstetrics and gynecology.

[42]  J. Dungan Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study , 2010 .

[43]  M. Vázquez High-Risk Human Papillomavirus DNA Testing: A Marker for Atypical Glandular Cells , 2007 .

[44]  S. Ciatto,et al.  Increasing trends of cervical adenocarcinoma incidence in Central Italy despite Extensive Screening Programme, 1985-2000. , 2004, Cancer Detection and Prevention.

[45]  E. Wilander,et al.  The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. , 2001, European journal of cancer.

[46]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.